ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1340	National Cancer Institute	Html	en	Cigar Smoking and Cancer	A fact sheet about the health risks associated with cigar smoking.	U.S. cigarettes 0.435012 safe level 0.447421 daily cigar smokers 0.575561 lung disease 0.3915 U.S. Department 0.408687 Tobacco Control Research 0.449796 cigarette wrappers 0.39436 fact sheet 0.390339 smoking cigarettes 0.411876 cigar smoke 0.9529 smaller cigar 0.493729 higher level 0.393813 tobacco wrapper 0.424842 tobacco 0.68829 little cigars 0.531809 cancer-causing chemicals 0.523406 single cigar 0.473523 tobacco equivalent 0.423502 tobacco smoke 0.637174 nicotine replacement therapy 0.395273 premium cigars 0.430441 cigar tobacco 0.599849 Yes. Cigar smoke 0.635443 Cigar smoking causes 0.545544 tobacco products 0.458198	nonporous cigar wrapper 0.527496 longer smoking time 0.409949 cigar sizes 0.492999 Step-by-Step Quit Guide 0.399635 nicotine replacement products 0.450092 cigar smokers 0.686977 cigarettes 0.521293 help quitting smoking 0.41788 NCI fact sheet 0.38899 cigar smoking 0.555875 Cigar wrappers 0.48618 cigarette smoke 0.705986 heart disease 0.392368 large cigars 0.512534 esophageal cancer risks 0.38664 cigarette tobacco 0.465692 cigars 0.636157 cigarette smokers 0.616772 cigar smoking.  Journal 0.511307 oral cavity cancers 0.409515 Services.  Reducing Tobacco 0.446373 Regular cigar smokers 0.574584 oral cavity 0.439868 safe tobacco product 0.484172	CLICK HERE
1388	National Cancer Institute	Html	en	Neuroblastoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood neuroblastoma.	neuroblastoma 0.976116 childhood cancer neuroblastoma 0.551793 major familial neuroblastoma 0.521543 neuroblastoma progression 0.496843 unresectable/disseminated neuroblastoma 0.495818 Neuroblastoma Study Group 0.537536 intermediate-risk neuroblastoma patients 0.580486 neuroblastoma molecular diagnostics 0.511987 hereditary neuroblastoma 0.561905 intermediate-risk neuroblastoma group 0.584332 low-risk neuroblastoma susceptibility 0.521417 neuroblastoma identifies chromothripsis 0.508284 neuroblastoma risk group 0.724371 low-risk neuroblastoma 0.617352 High-risk neuroblastoma tumors 0.54129 high-risk neuroblastoma 0.745428 neuroblastoma section 0.536455 neuroblastoma SNP association 0.525331 stage IV-S neuroblastoma 0.494981 neuroblastoma cell 0.546055 Neuroblastoma Pathology Committee 0.5037 et al. 0.867573 Neuroblastoma Pathology Classification 0.578039 neuroblastoma tumors 0.563844 stage iv neuroblastoma 0.527215	diagnostic neuroblastoma samples. 0.552115 international neuroblastoma 0.731336 international neuroblastoma staging 0.561855 neuroblastoma cases 0.533897 PUBMED Abstract 0.580731 multifocal neuroblastoma 0.525099 neuroblastoma cells 0.534711 aggressive MYC-driven neuroblastoma 0.504084 Pediatr Blood Cancer 0.580995 Oncology Group study 0.606704 Italian Neuroblastoma group 0.510786 international neuroblastoma risk 0.640282 high-risk neuroblastoma group 0.601822 intermediate-risk neuroblastoma 0.586941 International Neuroblastoma Pathology 0.642606 childhood neuroblastoma 0.512977 Abstract 0.706617 Clin Oncol 0.827663 low-risk neuroblastoma group 0.586425 Neuroblastoma Susceptibility Locus 0.517512 heterogeneous MYCN-amplified neuroblastoma 0.505216 neuroblastoma oncogene 0.499459 metastatic neuroblastoma 0.519613 oncology group 0.651154	CLICK HERE
1409	National Cancer Institute	Html	en	Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing ovarian, fallopian tube, and primary peritoneal cancers and about research aimed at the prevention of them.	cancer risk factors 0.421609 oral contraceptives 0.394634 cancer treatment 0.361951 Cancer prevention 0.515594 cancer prevention trials 0.422093 invasive ovarian cancer 0.476074 primary peritoneal cancers 0.449406 nonpolyposis colorectal cancer 0.387747 cancer protective factor 0.395471 decreased risk 0.397035 prevention clinical trials 0.392562 protective factors 0.425839 gene changes 0.362438 clinical trials 0.530283 Cancer Information Service 0.386071 following PDQ summaries 0.382587 PDQ cancer information 0.483395 ovarian cancer cells 0.47684 fallopian tube 0.63787 breast/ovarian cancer syndrome 0.3882 Prevention Editorial Board 0.384816 National Cancer Institute 0.445029 primary peritoneal cancer 0.60944 increased risk 0.383316	cancer information summary 0.437953 PDQ Ovarian 0.447122 breast cancer prevention 0.37908 ovarian cancer 0.978586 cancer patients 0.359808 Cancer Care page 0.379399 slightly increased risk 0.38086 Early ovarian cancer 0.493894 cancer risk factor 0.422611 PDQ summary 0.375317 cancer risk assessment 0.407064 NCI PDQ cancer 0.412389 cancer clinical trials 0.393106 risk factors 0.470948 peritoneal cancer prevention 0.426918 fallopian tubes 0.510186 cancer information summaries 0.390404 hormone replacement therapy 0.391262 comprehensive cancer information 0.390371 ovarian cancer prevention 0.478328 risk 0.594719 ovarian tissue 0.417842 ovarian cancer syndrome 0.488439	CLICK HERE
1459	National Cancer Institute	Html	en	Genetics of Endocrine and Neuroendocrine Neoplasias (PDQ®)–Health Professional Version	Endocrine and neuroendocrine neoplasias may be inherited in syndromes such as multiple endocrine neoplasia types 1 and 2 (MEN1 and MEN2), familial pheochromocytoma and paraganglioma, and Carney-Stratakis syndrome. Learn about the genetics, clinical manifestations, and management of these hereditary cancer syndromes in this expert-reviewed summary.	men1 gene 0.496062 endocrine neoplasia syndrome 0.465022 moderate-risk pathogenic variants 0.451346 Zollinger-Ellison syndrome 0.472267 gene pathogenic variant 0.461604 familial multiple endocrine 0.465896 MEN1 pathogenic variant. 0.494678 M918T pathogenic variants 0.452285 Ann Surg 0.450141 Dutch MEN1 Study 0.479758 gene pathogenic variants 0.465665 pathogenic variant detection 0.451143 pathogenic variant testing 0.449159 Common pathogenic variants 0.452259 C634R pathogenic variant 0.448895 recent Dutch MEN1 0.461537 family members 0.473057 MEN1 section 0.451905 specific pathogenic variants 0.452497 patients 0.486964 ATA-H pathogenic variants 0.452298 Preoperative multiple endocrine 0.451658 certain endocrine tumors 0.451569 Clin Endocrinol Metab 0.506906	MEN1 multicenter study 0.456509 pathogenic variant analysis 0.462761 et al. 0.511423 pancreaticoduodenal endocrine tumors 0.47075 MEN1 diagnosis 0.459578 MEN1 testing 0.457802 MEN1 pathogenic variants 0.509643 endocrine neoplasia type 0.912503 PUBMED Abstract 0.487944 multiple endocrine neoplasia 0.985247 pathogenic variants 0.602394 term pathogenic variant 0.454804 MEN1 Study Group 0.48033 pathogenic variant yield 0.450166 primary hyperparathyroidism 0.470964 RET pathogenic variant 0.455734 pathogenic variant prevalence 0.453316 RET pathogenic variants 0.474875 pancreatic endocrine tumors 0.459209 Abstract 0.518889 C634Y pathogenic variant 0.449059 calcitonin levels 0.449053 term multiple endocrine 0.45844 germline pathogenic variants 0.463296	CLICK HERE
1515	National Cancer Institute	Html	en	Breast Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of ductal carcinoma in situ and invasive breast cancer.	receptor positive breast 0.389112 recurrent breast cancer 0.41257 lymph node dissection 0.398428 body 0.421534 chemotherapy 0.384234 cyclin-dependent kinase inhibitor 0.375792 PDQ cancer information 0.374498 clinical trial search 0.376459 clinical trials 0.55567 lymph nodes 0.532453 breast cancer stage 0.396227 nearby lymph nodes 0.381968 clinical trial 0.460837 breast cancer prevention 0.382905 operable breast cancer 0.404481 lymph node biopsy 0.424733 sentinel lymph node 0.494651 negative breast cancer 0.393225 hormone receptor 0.507216 Breast Cancer section 0.382102 early localized breast 0.377075 metastatic breast cancer 0.529763 radiation therapy 0.516142 invasive breast cancer 0.40061	treatment 0.558809 cancer cells 0.554268 locoregional recurrent breast 0.376998 National Cancer Institute 0.382174 Breast Cancer Treatment 0.421137 hormone therapy 0.437437 positive breast cancer 0.437025 aromatase inhibitor therapy 0.411893 lymph vessels 0.386711 breast cancer cells 0.399587 breast cancer risk 0.404406 therapy 0.540165 breast cancer 0.932332 Hereditary breast cancer 0.400558 chest wall 0.386382 IIIC breast cancer 0.390142 Male Breast Cancer 0.401114 inflammatory breast cancer 0.490531 cancer clinical trials 0.394625 lymph node 0.49671 tumor 0.424316 treatment options 0.395579 information 0.445448 surgery 0.409957	CLICK HERE
1658	National Cancer Institute	Html	en	Childhood Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood medulloblastoma, nonmedulloblastoma embryonal tumors, and pineal tumors.	clinical trial 0.453805 treatment 0.609377 general information 0.246182 childhood cns 0.275323 nonmedulloblastoma embryonal tumors 0.299989 cancer cells 0.278431 embryonal tumors 0.938688 brain 0.391786 chemotherapy 0.262908 CNS embryonal tumors 0.85028 clinical trial search 0.248648	cancer clinical trials 0.254529 brain tumors 0.23742 stem cell rescue 0.406691 children 0.244267 radiation therapy 0.844353 clinical trials 0.725208 cancer 0.65116 standard treatment 0.256014 information 0.249598 spinal cord 0.615415 CNS embryonal tumor 0.222757	CLICK HERE
1764	National Cancer Institute	Html	en	Tea and Cancer Prevention	A fact sheet that summarizes the results of studies about tea and cancer prevention. Includes information about the ingredients of tea and safety considerations regarding tea consumption.	tea polyphenol levels 0.386589 Green tea intake 0.401876 oolong tea 0.430327 green tea extract 0.434777 green tea catechin 0.434487 mixed tea product 0.390858 green tea infusions 0.469418 Black tea accounts 0.426082 tea catechin group 0.406391 Tea polyphenol intake 0.383146 black tea consumption 0.458652 tea varies 0.383038 tea extract supplement 0.379754 tea bags 0.400306 particular tea beverage 0.399275 green tea polyphenol 0.422956 black tea group 0.40375 tea consumption 0.652621 tea products 0.407804 green tea consumption 0.479322 different green tea 0.428697 black tea 0.677083 S. Green tea 0.391643 tea leaves 0.426385 brewed tea 0.399059	N. Tea polyphenols 0.413159 white tea 0.407798 tea solids 0.391896 green tea supplement 0.413231 common tea 0.402087 hot tea 0.38785 tea drinking 0.433775 black tea drinking 0.402834 green tea supplements 0.453812 tea plants 0.38252 green tea 0.980769 X. Green tea 0.398746 instant tea mixes 0.411097 green tea drinking 0.395736 R. Green tea 0.399438 tea polyphenols 0.638268 green tea catechins 0.51662 green tea polyphenols 0.515146 popular tea 0.402474 et al 0.644372 cancer risk 0.405162 green tea extracts 0.454939 cancer 0.441469 drinking tea 0.381909	CLICK HERE
1993	National Cancer Institute	Html	es	Tratamiento del craneofaringioma infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del craneofaringioma infantil	radiocirugía estereotáctica 0.762185 siguientes procedimientos 0.374594 cráneo.ampliar craneotomía 0.361774 siguientes especialistas 0.367839 radioterapia causa 0.437652 vía oral 0.344906 rayos x 0.457932 PDQ Descripción 0.478828 encéfalo benignos 0.464072 rayos gamma 0.344103 efectos tardíos 0.944822 PDQ Efectos tardíos 0.500304 National Cancer Institute 0.34653 tumores benignos 0.729016	siguientes riesgos 0.333562 Instituto Nacional 0.381114 PDQ Tratamiento 0.757616 determinados cambios 0.335985 nuevos tipos 0.356873 Physician Data Query 0.470403 sistema nervioso central 0.413873 especial llamada acelerador 0.379394 Aboutâ„¢ Brain Tumors 0.36107 simple vista 0.352074 siguientes enlaces 0.33948 pequeño recipiente 0.345075 siguientes pruebas 0.387403	CLICK HERE
4288	National Cancer Institute	Html	en	Delirium and Cancer Treatment	Delirium is a confused mental state. Symptoms may include changes in thinking and sleeping. In cancer patients, it may be caused by medicine, dehydration, or happen at the end of life. Delirium may be mistaken for depression or dementia.	familiar possessions 0.460098 hyperactive delirium 0.731474 questions 0.420272 family member 0.493907 health care team 0.510247 brain tumors 0.464705 poor nutrition 0.45797 judgment 0.429189 awareness 0.413241 dehydration 0.454891 health care providers 0.496178 family members 0.628462 high doses 0.463949 risk factors 0.511453 Control surroundings 0.456835 patterns 0.413223 list 0.42027 bowels 0.414692 symptoms 0.455716 hypoactive delirium 0.762002 careful observation 0.458029 Early monitoring 0.462105 decision-making 0.411721 Mixed delirium 0.689111 older age 0.46515	dementia 0.412808 conditions 0.42534 mental state 0.468032 different treatments 0.463034 infection 0.411593 supportive care approaches 0.497253 sedation 0.440043 life 0.425096 causes 0.425024 certain medicines 0.522455 PDQ® summary 0.45633 end 0.425106 decisions 0.423293 behavior 0.413211 delirium 0.955275 short period 0.469724 main types 0.467622 advanced cancer 0.462991 patient changes 0.458323 withdrawal 0.412724 professional version 0.456367 doctor 0.420247 bladder 0.411574 time 0.413034	CLICK HERE
16715	National Cancer Institute	Html	en	Combining Targeted Therapies for Newly Diagnosed Metastatic Lung Cancer	Combining Targeted Therapies for Newly Diagnosed Metastatic Lung Cancer	different ways 0.50113 Afatinib Plus 0.525864 eligibility criteria 0.492811 cell growth 0.50521 M.D. 0.417708 Sarah B. Goldberg 0.619079 type 0.417261 toll 0.416537 lung cancer 0.900682 EGFR mutation-positive NSCLC 0.628765 Dr. Goldberg 0.509247 number 0.416777 EGFR inhibition 0.527024 mutations 0.419167 EGFR mutation-positive lung 0.62129 options 0.416767 combination 0.446178 clinical trial 0.506998 biomarkers 0.422468 response rate 0.492762 non-small cell lung 0.848673 protocol summary 0.517559 doctors 0.434669 EGFR inhibitors 0.527253 Erbitux®). 0.503443	FDA 0.432101 Advanced 0.418987 activity 0.417451 trial contact information 0.578358 EGFR Mutation-Positive Non-Small 0.656886 Drug Administration 0.495801 Phase II/III Trial 0.629587 Cetuximab Versus Afatinib 0.627245 Treatment-Naïve Patients 0.528367 investigator 0.417034 Dr. Sarah Goldberg 0.592518 EGFR protein 0.691134 trial’s principal 0.499034 first-line therapy 0.500906 cases 0.434794 Yale Cancer Center 0.605937 drugs 0.462999 progression-free survival 0.494968 EGFR inhibitor afatinib 0.642732 People 0.417276 tissue samples 0.494918 NCI Contact Center 0.571627 cell lung cancer 0.812241 time 0.416723	CLICK HERE